Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2009, p. 807-810, Vol. 47, No. 3
0095-1137/09/$08.00+0 doi:10.1128/JCM.01324-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Department of Pathology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1122, New York, New York 10029,1 Department of Medical Microbiology, Leiden University Medical Center, Albinusdreef 2, 2300RC Leiden, The Netherlands2
Received 11 July 2008/ Returned for modification 25 August 2008/ Accepted 12 December 2008
|
|
|---|
|
|
|---|
While the presumptive diagnosis of C. perfringens can be achieved by clinical and pathological findings, confirmation is routinely performed by conventional microbiological isolation and characterization methods including bacterial culture, biochemical analysis, and enzyme-linked immunosorbent assay (6, 8). Conventional culture procedures are expensive and time-consuming and detect only live microorganisms. Therefore, current conventional detection techniques are not applicable for the detection of nonviable bacteria, such as those found in formalin-fixed tissue samples. PCR is a well-accepted, rapid, and sensitive technique for the detection of microbial pathogens, particularly in situations in which low bacterial copy numbers are present (17). PCR assays have been used to identify C. perfringens in animals (3, 6, 9, 13, 17). However, no studies describe methods to detect and differentiate the various toxigenic types in formalin-fixed, paraffin-embedded human tissue samples. Therefore, we developed a sensitive PCR-based method for the detection of C. perfringens strains and their associated toxin genes in formalin-fixed, paraffin-embedded tissue samples in situations when diagnosis of the infection by culture is unavailable.
In order to confirm the sensitivity and specificity of the assay, four types of C. perfringens reference strains were obtained from American Type Culture Collection (ATCC; Manassas, VA): type A (ATCC 13124), type B (ATCC 3626), type C (ATCC 3628), and type D (ATCC 3629). Other bacterial strains, including Clostridium difficile (ATCC 9689), Clostridium sordellii (ATCC 9714), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Proteus vulgaris (ATCC 13315), and Salmonella enterica serovar Typhimurium (ATCC 4924), were also obtained. We then studied two autopsy cases in which bacterial infection was clinically unsuspected as the cause of death. In case one, emphysematous gastritis involving the proximal half of the stomach and distal esophagus and focal necrosis of lungs were found. In case two, grossly visible air spaces ("Swiss cheese" appearance) (Fig. 1A) were found in the liver, brain, heart, kidneys, spleen, and intestine. Microscopic examination of the tissue sections from various organs of both cases revealed spore-forming, boxcar-shaped, gram-positive bacilli, morphologically consistent with C. perfringens (Fig. 1A and B). PCR was performed to confirm the diagnosis of C. perfringens and for further toxinogenic genotyping of the bacteria using formalin-fixed, paraffin-embedded tissue blocks of the stomach (case 1) and liver (case 2) in which gram-positive bacilli were identified.
![]() View larger version (125K): [in a new window] |
FIG. 1. Identification of C. perfringens by macroscopic and microscopic examination. (A) Cut surface of liver (case 2) exhibiting multiple cystic air spaces ("Swiss cheese" appearance) lined by bacteria (left and right insets, magnifications of x10 and x40, respectively; both insets stained with hematoxylin and eosin). (B) Section of stomach (case 1) demonstrating colonization of gastric epithelium by numerous boxcar-shaped, gram-positive organisms.
|
Specific primers corresponding to the 16S rRNA gene (GenBank accession no. Y12669) (15) and to the alpha-toxin gene or cpa (GenBank accession no. X13608) (8), beta-toxin gene or cpb (GenBank accession no. X83275) (8), and epsilon-toxin gene or etx (GenBank accession no. X60694) (8) of C. perfringens were designed by using the sequence data obtained from GenBank (National Institute of Health, Bethesda, MD) and synthesized by Gene Link (Hawthorne, NY). Primers were designed for alpha-, beta-, and epsilon-toxin genes of C. perfringens, as these toxins are the major cause of human diseases (12, 16). Furthermore, detection of these genes allows for the molecular genotyping of C. perfringens (13). Primer sequences, locations of the primers, and sizes of the products are shown in Table 1.
|
View this table: [in a new window] |
TABLE 1. PCR primers used in this study
|
PCR amplification yielded the expected products for the 16S rRNA (279-bp), cpa (324-bp), cpb (196-bp), and etx (665-bp) genes (Fig. 2A). The assay sensitivity was determined using a serial 10-fold dilution of genomic DNA isolated from cultured C. perfringens. Since the cpb and etx genes are on plasmids, the exact copy numbers of these plasmids in these strains are unknown. Therefore, the copy number of genomic DNA was used to determine analytical sensitivity. The analytical sensitivity of the PCR assay for the 16S rRNA gene was 50 copies of genomic DNA and ranged from 50 (cpb and etx) to 500 (cpa) copies for the other genes (Fig. 2A). The lower sensitivity for cpa (500 copies) may be due to sequence variation of this gene in different strains or insufficient sensitivity of the primer (14).
![]() View larger version (59K): [in a new window] |
FIG. 2. Detection of 16S rRNA and toxin genes of C. perfringens by PCR. (A) Sensitivity of the PCR assay for the detection of 16S rRNA and toxin genes (cpa, cpb, and etx) of C. perfringens. Genomic DNA was serially diluted 10-fold from 5 x 105 to 5 copies. The results showed that the sensitivity of detecting each gene was between 50 and 500 copies. (B) Specific amplification of the 16S rRNA gene of C. perfringens (279 bp) by PCR. Lane 1, C. perfringens type B (5 x 105 copies); lane 2, C. perfringens type B (5 x 102 copies); lane 3, blank (no target); lane 4, C. difficile; lane 5, C. sordelli; lane 6, P. aeruginosa; lane 7, E. coli; lane 8, S. enterica serovar Typhimurium; lane 9, P. vulgaris. Lanes M in panels A and B contain DNA size markers (pBR322 DNA MspI digest). Genomic DNA (5 x 105 copies) was tested for bacteria other than C. perfringens.
|
As expected, the 16S rRNA gene (279 bp) and alpha-toxin gene (324 bp) were present in all types of C. perfringens, the beta-toxin gene (196 bp) was present in types B and C, and the epsilon-toxin gene (665 bp) was present in types B and D (Fig. 3A). These results indicate that selected toxin gene primers can reliably categorize C. perfringens into specific subtypes (8, 13).
![]() View larger version (51K): [in a new window] |
FIG. 3. Genotyping of C. perfringens by PCR. The DNAs extracted from C. perfringens types A to D (ATCC strains) (A) or from tissue sections of case 1 (stomach) and case 2 (liver) (B) were amplified using primers specific for the 16S rRNA gene and each toxin gene (cpa, cpb, and etx) by PCR. Lanes M contain DNA size markers (pBR322 DNA MspI digest).
|
As the majority of cases of gas gangrene are caused by C. perfringens (1), this assay can be used to confirm the diagnosis of C. perfringens gas gangrene, particularly in a situation where the only material available for microbiological testing is formalin-fixed, paraffin-embedded tissue. However, it has to be acknowledged that a negative result with the described PCR assay does not rule out the involvement of other, non-C. perfringens, gas gangrene-causing Clostridium species, such as C. welchii, C. septicum, C. novyi, and C. histolyticum.
In conclusion, the described PCR assay could be used to detect C. perfringens and simultaneously detect the presence of its specific toxin genes in formalin-fixed, paraffin-embedded tissue samples. These primer sets hold promise as a means of detecting C. perfringens and the genes that encode its principal toxins, but further optimization and confirmatory studies are needed. More importantly, to improve the clinical value of the assay, a similar PCR assay that includes other gas gangrene-causing Clostridium species (e.g., C. welchii, C. septicum, C. novyi, C. histolyticum) as well can now be developed.
Published ahead of print on 24 December 2008. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»